Diabetes & Endocrine

Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.

Second-generation sulfonylurea oral antidiabetic on the WHO Model List of Essential Medicines. Stimulates pancreatic beta-cell insulin secretion by blocking ATP-sensitive potassium channels. Indicated for type 2 diabetes mellitus.

Second-generation sulfonylurea oral antidiabetic on the WHO Model List of Essential Medicines. Stimulates pancreatic beta-cell insulin secretion by blocking ATP-sensitive potassium channels. Indicated for type 2 diabetes mellitus.

Gliclazide (Modified Release 30 mg, 60 mg) is a second-generation oral sulfonylurea with selective pancreatic tropism on the WHO Model List of Essential Medicines. It selectively binds to SUR1 receptors with fast reversible kinetics, restoring early first-phase insulin secretion and protecting vascular endothelium against oxidative stress via free radical-scavenging properties. Modified-release tablets provide steady 24-hour glycemic coverage with low hypoglycemia and weight gain risk. Indicated for type 2 diabetes mellitus in adults.

Gliclazide (Modified Release 30 mg, 60 mg) is a second-generation oral sulfonylurea with selective pancreatic tropism on the WHO Model List of Essential Medicines. It selectively binds to SUR1 receptors with fast reversible kinetics, restoring early first-phase insulin secretion and protecting vascular endothelium against oxidative stress via free radical-scavenging properties. Modified-release tablets provide steady 24-hour glycemic coverage with low hypoglycemia and weight gain risk. Indicated for type 2 diabetes mellitus in adults.

Glimepiride is a potent, third-generation oral sulfonylurea on the WHO Model List of Essential Medicines. It binds to the 65 kDa subunit of the sulfonylurea receptor (SUR1) on pancreatic beta-cell membranes, closing ATP-sensitive potassium channels, depolarizing the cell membrane, opening voltage-dependent calcium channels, and triggering exocytosis of pre-formed insulin granules. Exhibits rapid association and dissociation kinetics, resulting in physiologic insulin secretion with relatively lower risk of prolonged hypoglycemia compared to older sulfonylureas. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus.

Glimepiride is a potent, third-generation oral sulfonylurea on the WHO Model List of Essential Medicines. It binds to the 65 kDa subunit of the sulfonylurea receptor (SUR1) on pancreatic beta-cell membranes, closing ATP-sensitive potassium channels, depolarizing the cell membrane, opening voltage-dependent calcium channels, and triggering exocytosis of pre-formed insulin granules. Exhibits rapid association and dissociation kinetics, resulting in physiologic insulin secretion with relatively lower risk of prolonged hypoglycemia compared to older sulfonylureas. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus.

Second-generation sulfonylurea oral antidiabetic on the WHO Model List of Essential Medicines. Stimulates pancreatic beta-cell insulin secretion by blocking ATP-sensitive potassium channels. Indicated for type 2 diabetes mellitus.

Recombinant Human Insulin therapy on the WHO Model List of Essential Medicines. Restores glycemic control, facilitates glucose uptake, and suppresses hepatic glucose production in diabetes mellitus.

Recombinant Human Insulin formulation (Regular human insulin, Isophane NPH intermediate-acting insulin, or Biphasic premixed human/analogue insulin) on the WHO Model List of Essential Medicines. It replaces deficient endogenous insulin, binding to membrane insulin receptor tyrosine kinase to promote cellular glucose uptake into skeletal muscle and adipose tissue, stimulate glycogen and protein synthesis, and inhibit lipolysis and hepatic gluconeogenesis. Indicated for type 1 diabetes mellitus, type 2 diabetes mellitus uncontrolled on oral therapies, gestational diabetes, and diabetic ketoacidosis.

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Pioglitazone Hydrochloride (15 mg, 30 mg) is a thiazolidinedione (TZD) insulin sensitizer on the WHO Model List of Essential Medicines. It acts as a potent, selective agonist at peroxisome proliferator-activated receptor-gamma (PPAR-gamma) nuclear receptors, modulating the transcription of genes involved in glucose and lipid metabolism, substantially improving insulin sensitivity in skeletal muscle, liver, and adipose tissue, and preserving pancreatic beta-cell mass over time. Indicated as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus.

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Thyroxine Sodium (Levothyroxine, T4, 25 mcg - 150 mcg) is synthetic crystalline levothyroxine sodium on the WHO Model List of Essential Medicines. It is identical to endogenous T4 secreted by the human thyroid gland. In peripheral target tissues, it is deiodinated by iodothyronine deiodinases into active triiodothyronine (T3), which enters the cell nucleus to bind thyroid hormone receptors, regulating basal metabolic rate, protein synthesis, lipid and carbohydrate metabolism, and normal cardiovascular function. Narrow therapeutic index drug. Indicated for replacement therapy in primary, secondary, and tertiary hypothyroidism of any etiology, and pituitary TSH suppression in thyroid cancer.

Recombinant Human Insulin formulation (Regular human insulin, Isophane NPH intermediate-acting insulin, or Biphasic premixed human/analogue insulin) on the WHO Model List of Essential Medicines. It replaces deficient endogenous insulin, binding to membrane insulin receptor tyrosine kinase to promote cellular glucose uptake into skeletal muscle and adipose tissue, stimulate glycogen and protein synthesis, and inhibit lipolysis and hepatic gluconeogenesis. Indicated for type 1 diabetes mellitus, type 2 diabetes mellitus uncontrolled on oral therapies, gestational diabetes, and diabetic ketoacidosis.

Insulin Glargine (100 IU/mL) is a recombinant DNA-origin human insulin analogue with an ultra-long, peakless 24-hour pharmacokinetic profile on the WHO Model List of Essential Medicines. It contains two extra arginine residues at the B-chain C-terminus, shifting its isoelectric point to pH 6.7; upon subcutaneous injection into physiological neutral pH (7.4), it precipitates into a stable microcrystalline depot that releases insulin monomer slowly and constantly over 24 hours, simulating basal physiological insulin secretion. Indicated for once-daily basal glycemic control in type 1 and type 2 diabetes mellitus.

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Voglibose (0.2 mg, 0.3 mg) is an oral alpha-glucosidase inhibitor. It competitively and reversibly inhibits brush-border alpha-glucosidases (sucrase, maltase, isomaltase) in the small intestinal mucosa, delaying the enzymatic hydrolysis of dietary disaccharides and complex carbohydrates into absorbable monosaccharides, specifically flattening the postprandial glucose spike without stimulating insulin. Indicated for postprandial hyperglycemia in type 2 diabetes mellitus.

Gliclazide (Modified Release 30 mg, 60 mg) is a second-generation oral sulfonylurea with selective pancreatic tropism on the WHO Model List of Essential Medicines. It selectively binds to SUR1 receptors with fast reversible kinetics, restoring early first-phase insulin secretion and protecting vascular endothelium against oxidative stress via free radical-scavenging properties. Modified-release tablets provide steady 24-hour glycemic coverage with low hypoglycemia and weight gain risk. Indicated for type 2 diabetes mellitus in adults.

Acarbose (50 mg) is a microbial pseudotetrasaccharide competitive alpha-glucosidase and pancreatic alpha-amylase inhibitor on the WHO Model List of Essential Medicines. It retards digestion of complex starches and sucrose in the upper jejunum, shifting carbohydrate digestion to the lower bowel and blunting postprandial glycemic excursions. Indicated for type 2 diabetes mellitus.

Voglibose (0.2 mg, 0.3 mg) is an oral alpha-glucosidase inhibitor. It competitively and reversibly inhibits brush-border alpha-glucosidases (sucrase, maltase, isomaltase) in the small intestinal mucosa, delaying the enzymatic hydrolysis of dietary disaccharides and complex carbohydrates into absorbable monosaccharides, specifically flattening the postprandial glucose spike without stimulating insulin. Indicated for postprandial hyperglycemia in type 2 diabetes mellitus.

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Thyroxine Sodium (Levothyroxine, T4, 25 mcg - 150 mcg) is synthetic crystalline levothyroxine sodium on the WHO Model List of Essential Medicines. It is identical to endogenous T4 secreted by the human thyroid gland. In peripheral target tissues, it is deiodinated by iodothyronine deiodinases into active triiodothyronine (T3), which enters the cell nucleus to bind thyroid hormone receptors, regulating basal metabolic rate, protein synthesis, lipid and carbohydrate metabolism, and normal cardiovascular function. Narrow therapeutic index drug. Indicated for replacement therapy in primary, secondary, and tertiary hypothyroidism of any etiology, and pituitary TSH suppression in thyroid cancer.

Methimazole / Carbimazole (prodrug of methimazole) is a thionamide antithyroid drug on the WHO Model List of Essential Medicines. It inhibits the enzyme thyroid peroxidase (TPO), preventing the oxidation of iodide to iodine and blocking the organification and coupling of iodotyrosine residues on thyroglobulin, halting the synthesis of thyroid hormones T3 and T4. Indicated for the medical management of hyperthyroidism in Graves' disease, toxic multinodular goiter, preparation for radioactive iodine or thyroidectomy, and thyrotoxic crisis.

Methimazole / Carbimazole (prodrug of methimazole) is a thionamide antithyroid drug on the WHO Model List of Essential Medicines. It inhibits the enzyme thyroid peroxidase (TPO), preventing the oxidation of iodide to iodine and blocking the organification and coupling of iodotyrosine residues on thyroglobulin, halting the synthesis of thyroid hormones T3 and T4. Indicated for the medical management of hyperthyroidism in Graves' disease, toxic multinodular goiter, preparation for radioactive iodine or thyroidectomy, and thyrotoxic crisis.

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Glimepiride is a potent, third-generation oral sulfonylurea on the WHO Model List of Essential Medicines. It binds to the 65 kDa subunit of the sulfonylurea receptor (SUR1) on pancreatic beta-cell membranes, closing ATP-sensitive potassium channels, depolarizing the cell membrane, opening voltage-dependent calcium channels, and triggering exocytosis of pre-formed insulin granules. Exhibits rapid association and dissociation kinetics, resulting in physiologic insulin secretion with relatively lower risk of prolonged hypoglycemia compared to older sulfonylureas. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus.

Glimepiride is a potent, third-generation oral sulfonylurea on the WHO Model List of Essential Medicines. It binds to the 65 kDa subunit of the sulfonylurea receptor (SUR1) on pancreatic beta-cell membranes, closing ATP-sensitive potassium channels, depolarizing the cell membrane, opening voltage-dependent calcium channels, and triggering exocytosis of pre-formed insulin granules. Exhibits rapid association and dissociation kinetics, resulting in physiologic insulin secretion with relatively lower risk of prolonged hypoglycemia compared to older sulfonylureas. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus.

Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.

Recombinant Human Insulin formulation (Regular human insulin, Isophane NPH intermediate-acting insulin, or Biphasic premixed human/analogue insulin) on the WHO Model List of Essential Medicines. It replaces deficient endogenous insulin, binding to membrane insulin receptor tyrosine kinase to promote cellular glucose uptake into skeletal muscle and adipose tissue, stimulate glycogen and protein synthesis, and inhibit lipolysis and hepatic gluconeogenesis. Indicated for type 1 diabetes mellitus, type 2 diabetes mellitus uncontrolled on oral therapies, gestational diabetes, and diabetic ketoacidosis.

Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.

Recombinant Human Insulin therapy on the WHO Model List of Essential Medicines. Restores glycemic control, facilitates glucose uptake, and suppresses hepatic glucose production in diabetes mellitus.

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Pioglitazone Hydrochloride (15 mg, 30 mg) is a thiazolidinedione (TZD) insulin sensitizer on the WHO Model List of Essential Medicines. It acts as a potent, selective agonist at peroxisome proliferator-activated receptor-gamma (PPAR-gamma) nuclear receptors, modulating the transcription of genes involved in glucose and lipid metabolism, substantially improving insulin sensitivity in skeletal muscle, liver, and adipose tissue, and preserving pancreatic beta-cell mass over time. Indicated as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus.

Teneligliptin (20 mg) is a third-generation, highly selective, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. It features a unique J-shaped conformation that binds to subsite S1, S2, and S2-extensive pockets of the DPP-4 enzyme, achieving powerful enzyme inhibition (>80% at 24 hours) with a half-life of 24.2 hours. It is eliminated through dual hepatic and renal pathways, allowing standard once-daily dosing across all stages of chronic kidney disease (CKD) without dose adjustments. Indicated for type 2 diabetes mellitus as monotherapy or in combination with other oral antidiabetic agents.

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Metformin Hydrochloride and Teneligliptin combines an insulin sensitizer with a long-acting peptidomimetic DPP-4 inhibitor. Teneligliptin possesses a unique "J-shaped" chemical structure with five consecutive binding anchors on the DPP-4 enzyme, providing potent and prolonged (>24 hour) incretin stabilization without requiring dose reduction in renal impairment, while metformin controls fasting hyperglycemia. Indicated for type 2 diabetes mellitus in adult patients.

Metformin Hydrochloride and Teneligliptin combines an insulin sensitizer with a long-acting peptidomimetic DPP-4 inhibitor. Teneligliptin possesses a unique "J-shaped" chemical structure with five consecutive binding anchors on the DPP-4 enzyme, providing potent and prolonged (>24 hour) incretin stabilization without requiring dose reduction in renal impairment, while metformin controls fasting hyperglycemia. Indicated for type 2 diabetes mellitus in adult patients.

Thyroxine Sodium (Levothyroxine, T4, 25 mcg - 150 mcg) is synthetic crystalline levothyroxine sodium on the WHO Model List of Essential Medicines. It is identical to endogenous T4 secreted by the human thyroid gland. In peripheral target tissues, it is deiodinated by iodothyronine deiodinases into active triiodothyronine (T3), which enters the cell nucleus to bind thyroid hormone receptors, regulating basal metabolic rate, protein synthesis, lipid and carbohydrate metabolism, and normal cardiovascular function. Narrow therapeutic index drug. Indicated for replacement therapy in primary, secondary, and tertiary hypothyroidism of any etiology, and pituitary TSH suppression in thyroid cancer.

Orlistat Capsules 120 mg is an evidence-based antidiabetic and endocrine pharmaceutical formulation. It acts by regulating metabolic homeostasis, optimizing hormonal signaling pathways, and normalizing blood glucose levels.

Metformin Hydrochloride and Gliclazide (Modified Release) combines an insulin sensitizer with a selectively reversible sulfonylurea. Gliclazide selectively binds to pancreatic beta-cell SUR1 receptors with fast on-off association kinetics, restoring the physiological first-phase insulin secretory burst and offering lower hypoglycemia risk than glibenclamide, while metformin reduces hepatic glucose output. Indicated for type 2 diabetes mellitus when monotherapy provides insufficient glycemic control.

Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.

Recombinant Human Insulin therapy on the WHO Model List of Essential Medicines. Restores glycemic control, facilitates glucose uptake, and suppresses hepatic glucose production in diabetes mellitus.

Vildagliptin (50 mg, 100 mg SR) is a cyanopyrrolidine dipeptidyl peptidase-4 (DPP-4) inhibitor. It binds covalently to the catalytic site of DPP-4 with slow substrate-like kinetics, slowing enzyme dissociation and providing sustained incretin (GLP-1 and GIP) stabilization. This increases insulin secretion and suppresses inappropriate glucagon secretion in a glucose-dependent manner, eliminating intrinsic hypoglycemia risk. Indicated for the treatment of type 2 diabetes mellitus.

Metformin Hydrochloride and Vildagliptin is a weight-neutral, low-hypoglycemia dual antidiabetic formulation. Metformin decreases hepatic gluconeogenesis and intestinal glucose absorption, while vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, prevents the enzymatic degradation of endogenous incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion by alpha cells. Indicated for the management of type 2 diabetes mellitus inadequately controlled by metformin monotherapy.

Metformin Hydrochloride and Vildagliptin is a weight-neutral, low-hypoglycemia dual antidiabetic formulation. Metformin decreases hepatic gluconeogenesis and intestinal glucose absorption, while vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, prevents the enzymatic degradation of endogenous incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion by alpha cells. Indicated for the management of type 2 diabetes mellitus inadequately controlled by metformin monotherapy.

Canagliflozin Tablets 100 mg is an evidence-based antidiabetic and endocrine pharmaceutical formulation. It acts by regulating metabolic homeostasis, optimizing hormonal signaling pathways, and normalizing blood glucose levels.

Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.

Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.

Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.

Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.

Acarbose (50 mg) is a microbial pseudotetrasaccharide competitive alpha-glucosidase and pancreatic alpha-amylase inhibitor on the WHO Model List of Essential Medicines. It retards digestion of complex starches and sucrose in the upper jejunum, shifting carbohydrate digestion to the lower bowel and blunting postprandial glycemic excursions. Indicated for type 2 diabetes mellitus.

Dapagliflozin (5 mg, 10 mg) is a pioneer selective sodium-glucose co-transporter 2 (SGLT2) inhibitor on the WHO Model List of Essential Medicines. It acts in the S1 segment of the renal proximal tubule, blocking glucose and sodium reabsorption and promoting the urinary excretion of 70 to 80 grams of glucose per day. In addition to glycemic reduction, it induces osmotic diuresis, decreases intraglomerular pressure, reduces cardiac preload and afterload, and confers landmark cardio-renal protection. Indicated for type 2 diabetes mellitus, heart failure with reduced or preserved ejection fraction (HFrEF/HFpEF), and chronic kidney disease (CKD) to slow renal decline.

Empagliflozin (10 mg, 25 mg) is a highly selective SGLT2 inhibitor on the WHO Model List of Essential Medicines with landmark proven cardiovascular and renal mortality benefits. It selectively inhibits SGLT2 in the renal proximal convoluted tubules, promoting glycosuria and natriuresis, improving systemic hemodynamics, and reducing cardiac ventricular wall stress. Indicated for type 2 diabetes mellitus, reduction of cardiovascular death in adults with T2D and established CVD, heart failure (across the entire spectrum of LVEF), and chronic kidney disease.

Empagliflozin (10 mg, 25 mg) is a highly selective SGLT2 inhibitor on the WHO Model List of Essential Medicines with landmark proven cardiovascular and renal mortality benefits. It selectively inhibits SGLT2 in the renal proximal convoluted tubules, promoting glycosuria and natriuresis, improving systemic hemodynamics, and reducing cardiac ventricular wall stress. Indicated for type 2 diabetes mellitus, reduction of cardiovascular death in adults with T2D and established CVD, heart failure (across the entire spectrum of LVEF), and chronic kidney disease.

Insulin Glargine (100 IU/mL) is a recombinant DNA-origin human insulin analogue with an ultra-long, peakless 24-hour pharmacokinetic profile on the WHO Model List of Essential Medicines. It contains two extra arginine residues at the B-chain C-terminus, shifting its isoelectric point to pH 6.7; upon subcutaneous injection into physiological neutral pH (7.4), it precipitates into a stable microcrystalline depot that releases insulin monomer slowly and constantly over 24 hours, simulating basal physiological insulin secretion. Indicated for once-daily basal glycemic control in type 1 and type 2 diabetes mellitus.

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Metformin Hydrochloride and Gliclazide (Modified Release) combines an insulin sensitizer with a selectively reversible sulfonylurea. Gliclazide selectively binds to pancreatic beta-cell SUR1 receptors with fast on-off association kinetics, restoring the physiological first-phase insulin secretory burst and offering lower hypoglycemia risk than glibenclamide, while metformin reduces hepatic glucose output. Indicated for type 2 diabetes mellitus when monotherapy provides insufficient glycemic control.

Metformin, Glimepiride, and Pioglitazone is a comprehensive triple-combination oral antidiabetic therapy. Metformin (biguanide) reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity; glimepiride (second-generation sulfonylurea) stimulates insulin secretion by closing beta-cell ATP-sensitive potassium channels; and pioglitazone (thiazolidinedione) acts as a potent agonist at peroxisome proliferator-activated receptor-gamma (PPAR-gamma), improving insulin-mediated glucose disposal in adipose tissue and skeletal muscle while sparing beta cells. Indicated for type 2 diabetes mellitus uncontrolled on dual oral therapies.

Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Linagliptin (5 mg) is a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It binds tightly and pseudo-irreversibly to DPP-4 with 8-fold higher potency than other gliptins. Unlike other DPP-4 inhibitors, it is excreted predominantly unchanged via the enterohepatic bile system (95%) with less than 5% renal excretion. Consequently, it requires NO dose adjustments in patients with any degree of renal impairment or hepatic dysfunction, making it the DPP-4 inhibitor of choice in chronic kidney disease. Indicated for type 2 diabetes mellitus.

Saxagliptin Tablets 5mg is an evidence-based antidiabetic and endocrine pharmaceutical formulation. It acts by regulating metabolic homeostasis, optimizing hormonal signaling pathways, and normalizing blood glucose levels.

Metformin Hydrochloride and Sitagliptin is a landmark incretin-based dual antidiabetic combination on the WHO Model List of Essential Medicines. Sitagliptin selectively inhibits DPP-4, elevating active GLP-1 and GIP to enhance glucose-dependent insulin synthesis and suppress postprandial glucagon, while metformin addresses insulin resistance and decreases hepatic glucose production. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Metformin Hydrochloride and Sitagliptin is a landmark incretin-based dual antidiabetic combination on the WHO Model List of Essential Medicines. Sitagliptin selectively inhibits DPP-4, elevating active GLP-1 and GIP to enhance glucose-dependent insulin synthesis and suppress postprandial glucagon, while metformin addresses insulin resistance and decreases hepatic glucose production. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Sitagliptin Phosphate (50 mg, 100 mg) is an orally active, highly selective beta-amino acid-derived dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It competitive inhibits DPP-4, preventing the rapid enzymatic degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), prolonging postprandial active incretin levels. This stimulates glucose-dependent insulin secretion and suppresses postprandial glucagon secretion without causing hypoglycemia or weight gain. Indicated for type 2 diabetes mellitus as monotherapy or combination therapy.

Sitagliptin Phosphate (50 mg, 100 mg) is an orally active, highly selective beta-amino acid-derived dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It competitive inhibits DPP-4, preventing the rapid enzymatic degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), prolonging postprandial active incretin levels. This stimulates glucose-dependent insulin secretion and suppresses postprandial glucagon secretion without causing hypoglycemia or weight gain. Indicated for type 2 diabetes mellitus as monotherapy or combination therapy.

Metformin Hydrochloride and Vildagliptin is a weight-neutral, low-hypoglycemia dual antidiabetic formulation. Metformin decreases hepatic gluconeogenesis and intestinal glucose absorption, while vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, prevents the enzymatic degradation of endogenous incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion by alpha cells. Indicated for the management of type 2 diabetes mellitus inadequately controlled by metformin monotherapy.

Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.

Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.

Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.

Thyroxine Sodium (Levothyroxine, T4, 25 mcg - 150 mcg) is synthetic crystalline levothyroxine sodium on the WHO Model List of Essential Medicines. It is identical to endogenous T4 secreted by the human thyroid gland. In peripheral target tissues, it is deiodinated by iodothyronine deiodinases into active triiodothyronine (T3), which enters the cell nucleus to bind thyroid hormone receptors, regulating basal metabolic rate, protein synthesis, lipid and carbohydrate metabolism, and normal cardiovascular function. Narrow therapeutic index drug. Indicated for replacement therapy in primary, secondary, and tertiary hypothyroidism of any etiology, and pituitary TSH suppression in thyroid cancer.

Thyroxine Sodium (Levothyroxine, T4, 25 mcg - 150 mcg) is synthetic crystalline levothyroxine sodium on the WHO Model List of Essential Medicines. It is identical to endogenous T4 secreted by the human thyroid gland. In peripheral target tissues, it is deiodinated by iodothyronine deiodinases into active triiodothyronine (T3), which enters the cell nucleus to bind thyroid hormone receptors, regulating basal metabolic rate, protein synthesis, lipid and carbohydrate metabolism, and normal cardiovascular function. Narrow therapeutic index drug. Indicated for replacement therapy in primary, secondary, and tertiary hypothyroidism of any etiology, and pituitary TSH suppression in thyroid cancer.

Thyroxine Sodium (Levothyroxine, T4, 25 mcg - 150 mcg) is synthetic crystalline levothyroxine sodium on the WHO Model List of Essential Medicines. It is identical to endogenous T4 secreted by the human thyroid gland. In peripheral target tissues, it is deiodinated by iodothyronine deiodinases into active triiodothyronine (T3), which enters the cell nucleus to bind thyroid hormone receptors, regulating basal metabolic rate, protein synthesis, lipid and carbohydrate metabolism, and normal cardiovascular function. Narrow therapeutic index drug. Indicated for replacement therapy in primary, secondary, and tertiary hypothyroidism of any etiology, and pituitary TSH suppression in thyroid cancer.

Thyroxine Sodium (Levothyroxine, T4, 25 mcg - 150 mcg) is synthetic crystalline levothyroxine sodium on the WHO Model List of Essential Medicines. It is identical to endogenous T4 secreted by the human thyroid gland. In peripheral target tissues, it is deiodinated by iodothyronine deiodinases into active triiodothyronine (T3), which enters the cell nucleus to bind thyroid hormone receptors, regulating basal metabolic rate, protein synthesis, lipid and carbohydrate metabolism, and normal cardiovascular function. Narrow therapeutic index drug. Indicated for replacement therapy in primary, secondary, and tertiary hypothyroidism of any etiology, and pituitary TSH suppression in thyroid cancer.

Recombinant Human Insulin formulation (Regular human insulin, Isophane NPH intermediate-acting insulin, or Biphasic premixed human/analogue insulin) on the WHO Model List of Essential Medicines. It replaces deficient endogenous insulin, binding to membrane insulin receptor tyrosine kinase to promote cellular glucose uptake into skeletal muscle and adipose tissue, stimulate glycogen and protein synthesis, and inhibit lipolysis and hepatic gluconeogenesis. Indicated for type 1 diabetes mellitus, type 2 diabetes mellitus uncontrolled on oral therapies, gestational diabetes, and diabetic ketoacidosis.

Recombinant Human Insulin formulation (Regular human insulin, Isophane NPH intermediate-acting insulin, or Biphasic premixed human/analogue insulin) on the WHO Model List of Essential Medicines. It replaces deficient endogenous insulin, binding to membrane insulin receptor tyrosine kinase to promote cellular glucose uptake into skeletal muscle and adipose tissue, stimulate glycogen and protein synthesis, and inhibit lipolysis and hepatic gluconeogenesis. Indicated for type 1 diabetes mellitus, type 2 diabetes mellitus uncontrolled on oral therapies, gestational diabetes, and diabetic ketoacidosis.

Repaglinide (0.5 mg, 1 mg, 2 mg) is an oral carbamoylmethylbenzoic acid meglitinide analogue on the WHO Model List of Essential Medicines. It acts as a rapid-onset, short-acting prandial insulin secretagogue by closing ATP-sensitive potassium channels on pancreatic beta-cell membranes via a distinct binding site from sulfonylureas. Features rapid absorption and ultra-short elimination half-life (around 1 hour), allowing "one meal, one dose; no meal, no dose" flexibility. Indicated for type 2 diabetes mellitus, particularly in patients with irregular meal schedules or prominent postprandial hyperglycemia.

Repaglinide (0.5 mg, 1 mg, 2 mg) is an oral carbamoylmethylbenzoic acid meglitinide analogue on the WHO Model List of Essential Medicines. It acts as a rapid-onset, short-acting prandial insulin secretagogue by closing ATP-sensitive potassium channels on pancreatic beta-cell membranes via a distinct binding site from sulfonylureas. Features rapid absorption and ultra-short elimination half-life (around 1 hour), allowing "one meal, one dose; no meal, no dose" flexibility. Indicated for type 2 diabetes mellitus, particularly in patients with irregular meal schedules or prominent postprandial hyperglycemia.

Repaglinide (0.5 mg, 1 mg, 2 mg) is an oral carbamoylmethylbenzoic acid meglitinide analogue on the WHO Model List of Essential Medicines. It acts as a rapid-onset, short-acting prandial insulin secretagogue by closing ATP-sensitive potassium channels on pancreatic beta-cell membranes via a distinct binding site from sulfonylureas. Features rapid absorption and ultra-short elimination half-life (around 1 hour), allowing "one meal, one dose; no meal, no dose" flexibility. Indicated for type 2 diabetes mellitus, particularly in patients with irregular meal schedules or prominent postprandial hyperglycemia.

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Metformin Hydrochloride and Dapagliflozin unites a biguanide with an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor on the WHO Model List of Essential Medicines. Metformin reduces hepatic glucose production and enhances insulin sensitivity, while dapagliflozin acts insulin-independently in the proximal renal tubules to block glucose reabsorption, promoting the urinary excretion of approximately 70-80 grams of glucose per day (equating to 280-320 kcal/day), producing glycemic control, modest weight loss, and blood pressure reduction. Indicated for type 2 diabetes mellitus, with proven cardiorenal benefits.

Metformin Hydrochloride and Dapagliflozin unites a biguanide with an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor on the WHO Model List of Essential Medicines. Metformin reduces hepatic glucose production and enhances insulin sensitivity, while dapagliflozin acts insulin-independently in the proximal renal tubules to block glucose reabsorption, promoting the urinary excretion of approximately 70-80 grams of glucose per day (equating to 280-320 kcal/day), producing glycemic control, modest weight loss, and blood pressure reduction. Indicated for type 2 diabetes mellitus, with proven cardiorenal benefits.

Dapagliflozin (5 mg, 10 mg) is a pioneer selective sodium-glucose co-transporter 2 (SGLT2) inhibitor on the WHO Model List of Essential Medicines. It acts in the S1 segment of the renal proximal tubule, blocking glucose and sodium reabsorption and promoting the urinary excretion of 70 to 80 grams of glucose per day. In addition to glycemic reduction, it induces osmotic diuresis, decreases intraglomerular pressure, reduces cardiac preload and afterload, and confers landmark cardio-renal protection. Indicated for type 2 diabetes mellitus, heart failure with reduced or preserved ejection fraction (HFrEF/HFpEF), and chronic kidney disease (CKD) to slow renal decline.

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Evogliptin Tartarate 5mg Tablets is an evidence-based antidiabetic and endocrine pharmaceutical formulation. It acts by regulating metabolic homeostasis, optimizing hormonal signaling pathways, and normalizing blood glucose levels.

Glimepiride is a potent, third-generation oral sulfonylurea on the WHO Model List of Essential Medicines. It binds to the 65 kDa subunit of the sulfonylurea receptor (SUR1) on pancreatic beta-cell membranes, closing ATP-sensitive potassium channels, depolarizing the cell membrane, opening voltage-dependent calcium channels, and triggering exocytosis of pre-formed insulin granules. Exhibits rapid association and dissociation kinetics, resulting in physiologic insulin secretion with relatively lower risk of prolonged hypoglycemia compared to older sulfonylureas. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus.

Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.

Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.

Vildagliptin (50 mg, 100 mg SR) is a cyanopyrrolidine dipeptidyl peptidase-4 (DPP-4) inhibitor. It binds covalently to the catalytic site of DPP-4 with slow substrate-like kinetics, slowing enzyme dissociation and providing sustained incretin (GLP-1 and GIP) stabilization. This increases insulin secretion and suppresses inappropriate glucagon secretion in a glucose-dependent manner, eliminating intrinsic hypoglycemia risk. Indicated for the treatment of type 2 diabetes mellitus.

Metformin Hydrochloride and Remogliflozin Etabonate is a dual oral antidiabetic formulation. Remogliflozin is an ester prodrug of a selective SGLT2 inhibitor that promotes glycosuria via renal tubular filtration, while metformin controls basal hepatic glucose output. Indicated for glycemic control in adult patients with type 2 diabetes mellitus.

Remogliflozin Etabonate (100 mg) is an oral prodrug of remogliflozin, a selective inhibitor of renal SGLT2. It blocks glucose reabsorption in proximal renal tubules, increasing urinary glucose excretion and improving glycemic control without stimulating insulin. Indicated for the treatment of type 2 diabetes mellitus in adults.

Metformin Hydrochloride and Remogliflozin Etabonate is a dual oral antidiabetic formulation. Remogliflozin is an ester prodrug of a selective SGLT2 inhibitor that promotes glycosuria via renal tubular filtration, while metformin controls basal hepatic glucose output. Indicated for glycemic control in adult patients with type 2 diabetes mellitus.

Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.

Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.

Alpha-Ketoanalogue and Essential Amino Acids is an oral nutritional therapy for chronic kidney disease (CKD). It provides keto-analogues of essential amino acids that undergo transamination in the body, taking up amino groups from circulating urea nitrogen and converting into essential amino acids without generating new urea nitrogen, reducing uremic toxins and slowing the decline of GFR in pre-dialysis renal disease. Indicated for prevention and therapy of damages due to faulty or deficient protein metabolism in chronic kidney disease in connection with limited dietary protein intake (<= 40 g/day).

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Sitagliptin Phosphate (50 mg, 100 mg) is an orally active, highly selective beta-amino acid-derived dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It competitive inhibits DPP-4, preventing the rapid enzymatic degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), prolonging postprandial active incretin levels. This stimulates glucose-dependent insulin secretion and suppresses postprandial glucagon secretion without causing hypoglycemia or weight gain. Indicated for type 2 diabetes mellitus as monotherapy or combination therapy.

Sitagliptin Phosphate (50 mg, 100 mg) is an orally active, highly selective beta-amino acid-derived dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It competitive inhibits DPP-4, preventing the rapid enzymatic degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), prolonging postprandial active incretin levels. This stimulates glucose-dependent insulin secretion and suppresses postprandial glucagon secretion without causing hypoglycemia or weight gain. Indicated for type 2 diabetes mellitus as monotherapy or combination therapy.

Alogliptin 25mg Tablets is an evidence-based antidiabetic and endocrine pharmaceutical formulation. It acts by regulating metabolic homeostasis, optimizing hormonal signaling pathways, and normalizing blood glucose levels.

Linagliptin (5 mg) is a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It binds tightly and pseudo-irreversibly to DPP-4 with 8-fold higher potency than other gliptins. Unlike other DPP-4 inhibitors, it is excreted predominantly unchanged via the enterohepatic bile system (95%) with less than 5% renal excretion. Consequently, it requires NO dose adjustments in patients with any degree of renal impairment or hepatic dysfunction, making it the DPP-4 inhibitor of choice in chronic kidney disease. Indicated for type 2 diabetes mellitus.

Teneligliptin (20 mg) is a third-generation, highly selective, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. It features a unique J-shaped conformation that binds to subsite S1, S2, and S2-extensive pockets of the DPP-4 enzyme, achieving powerful enzyme inhibition (>80% at 24 hours) with a half-life of 24.2 hours. It is eliminated through dual hepatic and renal pathways, allowing standard once-daily dosing across all stages of chronic kidney disease (CKD) without dose adjustments. Indicated for type 2 diabetes mellitus as monotherapy or in combination with other oral antidiabetic agents.

Vildaglipitin 100mg Extended Release Tablets is an evidence-based antidiabetic and endocrine pharmaceutical formulation. It acts by regulating metabolic homeostasis, optimizing hormonal signaling pathways, and normalizing blood glucose levels.

Metformin Hydrochloride and Sitagliptin is a landmark incretin-based dual antidiabetic combination on the WHO Model List of Essential Medicines. Sitagliptin selectively inhibits DPP-4, elevating active GLP-1 and GIP to enhance glucose-dependent insulin synthesis and suppress postprandial glucagon, while metformin addresses insulin resistance and decreases hepatic glucose production. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Metformin Hydrochloride and Sitagliptin is a landmark incretin-based dual antidiabetic combination on the WHO Model List of Essential Medicines. Sitagliptin selectively inhibits DPP-4, elevating active GLP-1 and GIP to enhance glucose-dependent insulin synthesis and suppress postprandial glucagon, while metformin addresses insulin resistance and decreases hepatic glucose production. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Methimazole / Carbimazole (prodrug of methimazole) is a thionamide antithyroid drug on the WHO Model List of Essential Medicines. It inhibits the enzyme thyroid peroxidase (TPO), preventing the oxidation of iodide to iodine and blocking the organification and coupling of iodotyrosine residues on thyroglobulin, halting the synthesis of thyroid hormones T3 and T4. Indicated for the medical management of hyperthyroidism in Graves' disease, toxic multinodular goiter, preparation for radioactive iodine or thyroidectomy, and thyrotoxic crisis.

Methimazole / Carbimazole (prodrug of methimazole) is a thionamide antithyroid drug on the WHO Model List of Essential Medicines. It inhibits the enzyme thyroid peroxidase (TPO), preventing the oxidation of iodide to iodine and blocking the organification and coupling of iodotyrosine residues on thyroglobulin, halting the synthesis of thyroid hormones T3 and T4. Indicated for the medical management of hyperthyroidism in Graves' disease, toxic multinodular goiter, preparation for radioactive iodine or thyroidectomy, and thyrotoxic crisis.

Vildagliptin (50 mg, 100 mg SR) is a cyanopyrrolidine dipeptidyl peptidase-4 (DPP-4) inhibitor. It binds covalently to the catalytic site of DPP-4 with slow substrate-like kinetics, slowing enzyme dissociation and providing sustained incretin (GLP-1 and GIP) stabilization. This increases insulin secretion and suppresses inappropriate glucagon secretion in a glucose-dependent manner, eliminating intrinsic hypoglycemia risk. Indicated for the treatment of type 2 diabetes mellitus.

Vildagliptin (50 mg, 100 mg SR) is a cyanopyrrolidine dipeptidyl peptidase-4 (DPP-4) inhibitor. It binds covalently to the catalytic site of DPP-4 with slow substrate-like kinetics, slowing enzyme dissociation and providing sustained incretin (GLP-1 and GIP) stabilization. This increases insulin secretion and suppresses inappropriate glucagon secretion in a glucose-dependent manner, eliminating intrinsic hypoglycemia risk. Indicated for the treatment of type 2 diabetes mellitus.

Teneligliptin (20 mg) is a third-generation, highly selective, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. It features a unique J-shaped conformation that binds to subsite S1, S2, and S2-extensive pockets of the DPP-4 enzyme, achieving powerful enzyme inhibition (>80% at 24 hours) with a half-life of 24.2 hours. It is eliminated through dual hepatic and renal pathways, allowing standard once-daily dosing across all stages of chronic kidney disease (CKD) without dose adjustments. Indicated for type 2 diabetes mellitus as monotherapy or in combination with other oral antidiabetic agents.

Metformin Hydrochloride and Vildagliptin is a weight-neutral, low-hypoglycemia dual antidiabetic formulation. Metformin decreases hepatic gluconeogenesis and intestinal glucose absorption, while vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, prevents the enzymatic degradation of endogenous incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion by alpha cells. Indicated for the management of type 2 diabetes mellitus inadequately controlled by metformin monotherapy.

Voglibose (0.2 mg, 0.3 mg) is an oral alpha-glucosidase inhibitor. It competitively and reversibly inhibits brush-border alpha-glucosidases (sucrase, maltase, isomaltase) in the small intestinal mucosa, delaying the enzymatic hydrolysis of dietary disaccharides and complex carbohydrates into absorbable monosaccharides, specifically flattening the postprandial glucose spike without stimulating insulin. Indicated for postprandial hyperglycemia in type 2 diabetes mellitus.

Voglibose (0.2 mg, 0.3 mg) is an oral alpha-glucosidase inhibitor. It competitively and reversibly inhibits brush-border alpha-glucosidases (sucrase, maltase, isomaltase) in the small intestinal mucosa, delaying the enzymatic hydrolysis of dietary disaccharides and complex carbohydrates into absorbable monosaccharides, specifically flattening the postprandial glucose spike without stimulating insulin. Indicated for postprandial hyperglycemia in type 2 diabetes mellitus.

Voglibose (0.2 mg, 0.3 mg) is an oral alpha-glucosidase inhibitor. It competitively and reversibly inhibits brush-border alpha-glucosidases (sucrase, maltase, isomaltase) in the small intestinal mucosa, delaying the enzymatic hydrolysis of dietary disaccharides and complex carbohydrates into absorbable monosaccharides, specifically flattening the postprandial glucose spike without stimulating insulin. Indicated for postprandial hyperglycemia in type 2 diabetes mellitus.

Voglibose (0.2 mg, 0.3 mg) is an oral alpha-glucosidase inhibitor. It competitively and reversibly inhibits brush-border alpha-glucosidases (sucrase, maltase, isomaltase) in the small intestinal mucosa, delaying the enzymatic hydrolysis of dietary disaccharides and complex carbohydrates into absorbable monosaccharides, specifically flattening the postprandial glucose spike without stimulating insulin. Indicated for postprandial hyperglycemia in type 2 diabetes mellitus.

Teneligliptin (20 mg) is a third-generation, highly selective, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. It features a unique J-shaped conformation that binds to subsite S1, S2, and S2-extensive pockets of the DPP-4 enzyme, achieving powerful enzyme inhibition (>80% at 24 hours) with a half-life of 24.2 hours. It is eliminated through dual hepatic and renal pathways, allowing standard once-daily dosing across all stages of chronic kidney disease (CKD) without dose adjustments. Indicated for type 2 diabetes mellitus as monotherapy or in combination with other oral antidiabetic agents.

Teneligliptin (20 mg) is a third-generation, highly selective, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. It features a unique J-shaped conformation that binds to subsite S1, S2, and S2-extensive pockets of the DPP-4 enzyme, achieving powerful enzyme inhibition (>80% at 24 hours) with a half-life of 24.2 hours. It is eliminated through dual hepatic and renal pathways, allowing standard once-daily dosing across all stages of chronic kidney disease (CKD) without dose adjustments. Indicated for type 2 diabetes mellitus as monotherapy or in combination with other oral antidiabetic agents.

Thyroxine Sodium (Levothyroxine, T4, 25 mcg - 150 mcg) is synthetic crystalline levothyroxine sodium on the WHO Model List of Essential Medicines. It is identical to endogenous T4 secreted by the human thyroid gland. In peripheral target tissues, it is deiodinated by iodothyronine deiodinases into active triiodothyronine (T3), which enters the cell nucleus to bind thyroid hormone receptors, regulating basal metabolic rate, protein synthesis, lipid and carbohydrate metabolism, and normal cardiovascular function. Narrow therapeutic index drug. Indicated for replacement therapy in primary, secondary, and tertiary hypothyroidism of any etiology, and pituitary TSH suppression in thyroid cancer.

Metformin Hydrochloride and Dapagliflozin unites a biguanide with an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor on the WHO Model List of Essential Medicines. Metformin reduces hepatic glucose production and enhances insulin sensitivity, while dapagliflozin acts insulin-independently in the proximal renal tubules to block glucose reabsorption, promoting the urinary excretion of approximately 70-80 grams of glucose per day (equating to 280-320 kcal/day), producing glycemic control, modest weight loss, and blood pressure reduction. Indicated for type 2 diabetes mellitus, with proven cardiorenal benefits.

Sitagliptin Phosphate (50 mg, 100 mg) is an orally active, highly selective beta-amino acid-derived dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It competitive inhibits DPP-4, preventing the rapid enzymatic degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), prolonging postprandial active incretin levels. This stimulates glucose-dependent insulin secretion and suppresses postprandial glucagon secretion without causing hypoglycemia or weight gain. Indicated for type 2 diabetes mellitus as monotherapy or combination therapy.

Metformin Hydrochloride and Sitagliptin is a landmark incretin-based dual antidiabetic combination on the WHO Model List of Essential Medicines. Sitagliptin selectively inhibits DPP-4, elevating active GLP-1 and GIP to enhance glucose-dependent insulin synthesis and suppress postprandial glucagon, while metformin addresses insulin resistance and decreases hepatic glucose production. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Metformin Hydrochloride and Sitagliptin is a landmark incretin-based dual antidiabetic combination on the WHO Model List of Essential Medicines. Sitagliptin selectively inhibits DPP-4, elevating active GLP-1 and GIP to enhance glucose-dependent insulin synthesis and suppress postprandial glucagon, while metformin addresses insulin resistance and decreases hepatic glucose production. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Metformin Hydrochloride and Dapagliflozin unites a biguanide with an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor on the WHO Model List of Essential Medicines. Metformin reduces hepatic glucose production and enhances insulin sensitivity, while dapagliflozin acts insulin-independently in the proximal renal tubules to block glucose reabsorption, promoting the urinary excretion of approximately 70-80 grams of glucose per day (equating to 280-320 kcal/day), producing glycemic control, modest weight loss, and blood pressure reduction. Indicated for type 2 diabetes mellitus, with proven cardiorenal benefits.

Sitagliptin Phosphate (50 mg, 100 mg) is an orally active, highly selective beta-amino acid-derived dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It competitive inhibits DPP-4, preventing the rapid enzymatic degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), prolonging postprandial active incretin levels. This stimulates glucose-dependent insulin secretion and suppresses postprandial glucagon secretion without causing hypoglycemia or weight gain. Indicated for type 2 diabetes mellitus as monotherapy or combination therapy.

Linagliptin (5 mg) is a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It binds tightly and pseudo-irreversibly to DPP-4 with 8-fold higher potency than other gliptins. Unlike other DPP-4 inhibitors, it is excreted predominantly unchanged via the enterohepatic bile system (95%) with less than 5% renal excretion. Consequently, it requires NO dose adjustments in patients with any degree of renal impairment or hepatic dysfunction, making it the DPP-4 inhibitor of choice in chronic kidney disease. Indicated for type 2 diabetes mellitus.

Imeglimin Hydrochloride (500 mg, 1000 mg) is a first-in-class oral tetrahydrotriazine derivative "glimin" antidiabetic agent. It targets mitochondrial bioenergetics across multiple organs: in the pancreas, it restores glucose-stimulated insulin secretion by increasing mitochondrial ATP and closing K_ATP channels while protecting beta cells against apoptosis; in the liver, it inhibits complex I of the respiratory chain, suppressing excessive gluconeogenesis; and in skeletal muscle, it enhances complex III activity, improving mitochondrial fatty acid oxidation and glucose uptake. Indicated for the treatment of type 2 diabetes mellitus as monotherapy or adjunct to other antidiabetic agents.

Imeglimin Hydrochloride (500 mg, 1000 mg) is a first-in-class oral tetrahydrotriazine derivative "glimin" antidiabetic agent. It targets mitochondrial bioenergetics across multiple organs: in the pancreas, it restores glucose-stimulated insulin secretion by increasing mitochondrial ATP and closing K_ATP channels while protecting beta cells against apoptosis; in the liver, it inhibits complex I of the respiratory chain, suppressing excessive gluconeogenesis; and in skeletal muscle, it enhances complex III activity, improving mitochondrial fatty acid oxidation and glucose uptake. Indicated for the treatment of type 2 diabetes mellitus as monotherapy or adjunct to other antidiabetic agents.

Linagliptin (5 mg) is a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It binds tightly and pseudo-irreversibly to DPP-4 with 8-fold higher potency than other gliptins. Unlike other DPP-4 inhibitors, it is excreted predominantly unchanged via the enterohepatic bile system (95%) with less than 5% renal excretion. Consequently, it requires NO dose adjustments in patients with any degree of renal impairment or hepatic dysfunction, making it the DPP-4 inhibitor of choice in chronic kidney disease. Indicated for type 2 diabetes mellitus.

Linagliptin (5 mg) is a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It binds tightly and pseudo-irreversibly to DPP-4 with 8-fold higher potency than other gliptins. Unlike other DPP-4 inhibitors, it is excreted predominantly unchanged via the enterohepatic bile system (95%) with less than 5% renal excretion. Consequently, it requires NO dose adjustments in patients with any degree of renal impairment or hepatic dysfunction, making it the DPP-4 inhibitor of choice in chronic kidney disease. Indicated for type 2 diabetes mellitus.

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Linagliptin (5 mg) is a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It binds tightly and pseudo-irreversibly to DPP-4 with 8-fold higher potency than other gliptins. Unlike other DPP-4 inhibitors, it is excreted predominantly unchanged via the enterohepatic bile system (95%) with less than 5% renal excretion. Consequently, it requires NO dose adjustments in patients with any degree of renal impairment or hepatic dysfunction, making it the DPP-4 inhibitor of choice in chronic kidney disease. Indicated for type 2 diabetes mellitus.

Linagliptin (5 mg) is a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It binds tightly and pseudo-irreversibly to DPP-4 with 8-fold higher potency than other gliptins. Unlike other DPP-4 inhibitors, it is excreted predominantly unchanged via the enterohepatic bile system (95%) with less than 5% renal excretion. Consequently, it requires NO dose adjustments in patients with any degree of renal impairment or hepatic dysfunction, making it the DPP-4 inhibitor of choice in chronic kidney disease. Indicated for type 2 diabetes mellitus.

Lobeglitazone Sulfate Tablets 0.5mg is an evidence-based antidiabetic and endocrine pharmaceutical formulation. It acts by regulating metabolic homeostasis, optimizing hormonal signaling pathways, and normalizing blood glucose levels.

Metformin Hydrochloride and Sitagliptin is a landmark incretin-based dual antidiabetic combination on the WHO Model List of Essential Medicines. Sitagliptin selectively inhibits DPP-4, elevating active GLP-1 and GIP to enhance glucose-dependent insulin synthesis and suppress postprandial glucagon, while metformin addresses insulin resistance and decreases hepatic glucose production. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Metformin Hydrochloride and Teneligliptin combines an insulin sensitizer with a long-acting peptidomimetic DPP-4 inhibitor. Teneligliptin possesses a unique "J-shaped" chemical structure with five consecutive binding anchors on the DPP-4 enzyme, providing potent and prolonged (>24 hour) incretin stabilization without requiring dose reduction in renal impairment, while metformin controls fasting hyperglycemia. Indicated for type 2 diabetes mellitus in adult patients.

Metformin Hydrochloride and Teneligliptin combines an insulin sensitizer with a long-acting peptidomimetic DPP-4 inhibitor. Teneligliptin possesses a unique "J-shaped" chemical structure with five consecutive binding anchors on the DPP-4 enzyme, providing potent and prolonged (>24 hour) incretin stabilization without requiring dose reduction in renal impairment, while metformin controls fasting hyperglycemia. Indicated for type 2 diabetes mellitus in adult patients.

Metformin Hydrochloride and Vildagliptin is a weight-neutral, low-hypoglycemia dual antidiabetic formulation. Metformin decreases hepatic gluconeogenesis and intestinal glucose absorption, while vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, prevents the enzymatic degradation of endogenous incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion by alpha cells. Indicated for the management of type 2 diabetes mellitus inadequately controlled by metformin monotherapy.

Metformin Hydrochloride and Vildagliptin is a weight-neutral, low-hypoglycemia dual antidiabetic formulation. Metformin decreases hepatic gluconeogenesis and intestinal glucose absorption, while vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, prevents the enzymatic degradation of endogenous incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion by alpha cells. Indicated for the management of type 2 diabetes mellitus inadequately controlled by metformin monotherapy.

Metformin Hydrochloride and Vildagliptin is a weight-neutral, low-hypoglycemia dual antidiabetic formulation. Metformin decreases hepatic gluconeogenesis and intestinal glucose absorption, while vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, prevents the enzymatic degradation of endogenous incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion by alpha cells. Indicated for the management of type 2 diabetes mellitus inadequately controlled by metformin monotherapy.

Metformin Hydrochloride and Vildagliptin is a weight-neutral, low-hypoglycemia dual antidiabetic formulation. Metformin decreases hepatic gluconeogenesis and intestinal glucose absorption, while vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, prevents the enzymatic degradation of endogenous incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion by alpha cells. Indicated for the management of type 2 diabetes mellitus inadequately controlled by metformin monotherapy.

Metformin Hydrochloride and Gliclazide (Modified Release) combines an insulin sensitizer with a selectively reversible sulfonylurea. Gliclazide selectively binds to pancreatic beta-cell SUR1 receptors with fast on-off association kinetics, restoring the physiological first-phase insulin secretory burst and offering lower hypoglycemia risk than glibenclamide, while metformin reduces hepatic glucose output. Indicated for type 2 diabetes mellitus when monotherapy provides insufficient glycemic control.

Metformin Hydrochloride and Vildagliptin is a weight-neutral, low-hypoglycemia dual antidiabetic formulation. Metformin decreases hepatic gluconeogenesis and intestinal glucose absorption, while vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, prevents the enzymatic degradation of endogenous incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion by alpha cells. Indicated for the management of type 2 diabetes mellitus inadequately controlled by metformin monotherapy.

Metformin Hydrochloride and Vildagliptin is a weight-neutral, low-hypoglycemia dual antidiabetic formulation. Metformin decreases hepatic gluconeogenesis and intestinal glucose absorption, while vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, prevents the enzymatic degradation of endogenous incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion by alpha cells. Indicated for the management of type 2 diabetes mellitus inadequately controlled by metformin monotherapy.

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).

Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.

Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.

Metformin Hydrochloride and Teneligliptin combines an insulin sensitizer with a long-acting peptidomimetic DPP-4 inhibitor. Teneligliptin possesses a unique "J-shaped" chemical structure with five consecutive binding anchors on the DPP-4 enzyme, providing potent and prolonged (>24 hour) incretin stabilization without requiring dose reduction in renal impairment, while metformin controls fasting hyperglycemia. Indicated for type 2 diabetes mellitus in adult patients.

Metformin Hydrochloride and Teneligliptin combines an insulin sensitizer with a long-acting peptidomimetic DPP-4 inhibitor. Teneligliptin possesses a unique "J-shaped" chemical structure with five consecutive binding anchors on the DPP-4 enzyme, providing potent and prolonged (>24 hour) incretin stabilization without requiring dose reduction in renal impairment, while metformin controls fasting hyperglycemia. Indicated for type 2 diabetes mellitus in adult patients.

Thyroxine Sodium (Levothyroxine, T4, 25 mcg - 150 mcg) is synthetic crystalline levothyroxine sodium on the WHO Model List of Essential Medicines. It is identical to endogenous T4 secreted by the human thyroid gland. In peripheral target tissues, it is deiodinated by iodothyronine deiodinases into active triiodothyronine (T3), which enters the cell nucleus to bind thyroid hormone receptors, regulating basal metabolic rate, protein synthesis, lipid and carbohydrate metabolism, and normal cardiovascular function. Narrow therapeutic index drug. Indicated for replacement therapy in primary, secondary, and tertiary hypothyroidism of any etiology, and pituitary TSH suppression in thyroid cancer.

Vildagliptin (50 mg, 100 mg SR) is a cyanopyrrolidine dipeptidyl peptidase-4 (DPP-4) inhibitor. It binds covalently to the catalytic site of DPP-4 with slow substrate-like kinetics, slowing enzyme dissociation and providing sustained incretin (GLP-1 and GIP) stabilization. This increases insulin secretion and suppresses inappropriate glucagon secretion in a glucose-dependent manner, eliminating intrinsic hypoglycemia risk. Indicated for the treatment of type 2 diabetes mellitus.

Metformin Hydrochloride and Gliclazide (Modified Release) combines an insulin sensitizer with a selectively reversible sulfonylurea. Gliclazide selectively binds to pancreatic beta-cell SUR1 receptors with fast on-off association kinetics, restoring the physiological first-phase insulin secretory burst and offering lower hypoglycemia risk than glibenclamide, while metformin reduces hepatic glucose output. Indicated for type 2 diabetes mellitus when monotherapy provides insufficient glycemic control.

Metformin Hydrochloride and Gliclazide (Modified Release) combines an insulin sensitizer with a selectively reversible sulfonylurea. Gliclazide selectively binds to pancreatic beta-cell SUR1 receptors with fast on-off association kinetics, restoring the physiological first-phase insulin secretory burst and offering lower hypoglycemia risk than glibenclamide, while metformin reduces hepatic glucose output. Indicated for type 2 diabetes mellitus when monotherapy provides insufficient glycemic control.

Orlistat Capsules 60Mg is an evidence-based antidiabetic and endocrine pharmaceutical formulation. It acts by regulating metabolic homeostasis, optimizing hormonal signaling pathways, and normalizing blood glucose levels.

Glimepiride and Pioglitazone is an oral dual-mechanism antidiabetic combination. Glimepiride stimulates rapid beta-cell insulin release, while pioglitazone enhances peripheral insulin sensitivity in skeletal muscle and adipose tissue via PPAR-gamma receptor activation, providing durable glycemic control. Indicated for type 2 diabetes mellitus uncontrolled on monotherapy.

Metformin Hydrochloride and Sitagliptin is a landmark incretin-based dual antidiabetic combination on the WHO Model List of Essential Medicines. Sitagliptin selectively inhibits DPP-4, elevating active GLP-1 and GIP to enhance glucose-dependent insulin synthesis and suppress postprandial glucagon, while metformin addresses insulin resistance and decreases hepatic glucose production. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Metformin Hydrochloride and Gliclazide (Modified Release) combines an insulin sensitizer with a selectively reversible sulfonylurea. Gliclazide selectively binds to pancreatic beta-cell SUR1 receptors with fast on-off association kinetics, restoring the physiological first-phase insulin secretory burst and offering lower hypoglycemia risk than glibenclamide, while metformin reduces hepatic glucose output. Indicated for type 2 diabetes mellitus when monotherapy provides insufficient glycemic control.

Metformin Hydrochloride and Gliclazide (Modified Release) combines an insulin sensitizer with a selectively reversible sulfonylurea. Gliclazide selectively binds to pancreatic beta-cell SUR1 receptors with fast on-off association kinetics, restoring the physiological first-phase insulin secretory burst and offering lower hypoglycemia risk than glibenclamide, while metformin reduces hepatic glucose output. Indicated for type 2 diabetes mellitus when monotherapy provides insufficient glycemic control.